ARVINAS, INC. Operating Lease, Right-of-Use Asset, Amortization Expense
ARVINAS, INC. (ARVN) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $900.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2026-08-04
- ARVINAS, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-06-30 was $500.00K, a 16.67% decline year-over-year.
- ARVINAS, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-03-31 was $400.00K, a 33.33% decline year-over-year.
- ARVINAS, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-12-31 was $500.00K, a 0.00% change year-over-year.
- ARVINAS, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-09-30 was $500.00K, a 0.00% change year-over-year.
- ARVINAS, INC. operating lease, right-of-use asset, amortization expense for fiscal 2025 was $2.20M, a 10.00% increase from fiscal 2024.
- ARVINAS, INC. operating lease, right-of-use asset, amortization expense for fiscal 2024 was $2.00M, a 5.26% increase from fiscal 2023.
- ARVINAS, INC. operating lease, right-of-use asset, amortization expense for fiscal 2023 was $1.90M, a 0.00% change from fiscal 2022.
- ARVINAS, INC. operating lease, right-of-use asset, amortization expense for fiscal 2022 was $1.90M, a 58.33% increase from fiscal 2021.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $500.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $900.00K 10-Q · filed 2026-08-04 | $1.40M derived: sum of 3 quarters · filed 2026-08-04 | $1.90M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $400.00K 10-Q · filed 2026-05-11 | $900.00K derived: sum of 2 quarters · filed 2026-05-11 | $1.40M derived: sum of 3 quarters · filed 2026-05-11 | $2.00M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $500.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $1.00M derived: sum of 2 quarters · filed 2026-02-24 | $1.60M derived: sum of 3 quarters · filed 2026-08-04 | $2.20M 10-K · filed 2026-02-24 |
| 2025-09-30 | $500.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $1.10M derived: sum of 2 quarters · filed 2026-08-04 | $1.70M 10-Q · filed 2025-11-05 | $2.20M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $600.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $1.20M 10-Q · filed 2026-08-04 | $1.70M derived: sum of 3 quarters · filed 2026-08-04 | $2.20M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $600.00K 10-Q · filed 2026-05-11 | $1.10M derived: sum of 2 quarters · filed 2026-05-11 | $1.60M derived: sum of 3 quarters · filed 2026-05-11 | $2.10M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $500.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $1.00M derived: sum of 2 quarters · filed 2026-02-24 | $1.50M derived: sum of 3 quarters · filed 2026-02-24 | $2.00M 10-K · filed 2026-02-24 |
| 2024-09-30 | $500.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $1.00M derived: sum of 2 quarters · filed 2025-11-05 | $1.50M 10-Q · filed 2025-11-05 | $2.00M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | $500.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $1.00M 10-Q · filed 2025-08-06 | $1.50M derived: sum of 3 quarters · filed 2026-02-24 | $2.00M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | $500.00K 10-Q · filed 2025-05-01 | $1.00M derived: sum of 2 quarters · filed 2026-02-24 | $1.50M derived: sum of 3 quarters · filed 2026-02-24 | $1.90M derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | $500.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $1.00M derived: sum of 2 quarters · filed 2026-02-24 | $1.40M derived: sum of 3 quarters · filed 2026-02-24 | $1.90M 10-K · filed 2026-02-24 |
| 2023-09-30 | $500.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-30 | $900.00K derived: sum of 2 quarters · filed 2024-10-30 | $1.40M 10-Q · filed 2024-10-30 | $1.80M derived: sum of 4 quarters · filed 2025-02-11 |
| 2023-06-30 | $400.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-30 | $900.00K 10-Q · filed 2024-07-30 | $1.30M derived: sum of 3 quarters · filed 2025-02-11 | $1.80M derived: sum of 4 quarters · filed 2025-02-11 |
| 2023-03-31 | $500.00K 10-Q · filed 2024-05-07 | $900.00K derived: sum of 2 quarters · filed 2025-02-11 | $1.40M derived: sum of 3 quarters · filed 2025-02-11 | $1.80M derived: sum of 4 quarters · filed 2025-02-11 |
| 2022-12-31 | $400.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-11 | $900.00K derived: sum of 2 quarters · filed 2025-02-11 | $1.30M derived: sum of 3 quarters · filed 2025-02-11 | $1.90M 10-K · filed 2025-02-11 |
| 2022-09-30 | $500.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $900.00K derived: sum of 2 quarters · filed 2023-11-07 | $1.50M 10-Q · filed 2023-11-07 | $1.80M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | $400.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $1.00M 10-Q · filed 2023-08-08 | $1.30M derived: sum of 3 quarters · filed 2024-02-27 | $1.60M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | $600.00K 10-Q · filed 2023-05-05 | $900.00K derived: sum of 2 quarters · filed 2024-02-27 | $1.20M derived: sum of 3 quarters · filed 2024-02-27 | $1.50M derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | $300.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $600.00K derived: sum of 2 quarters · filed 2024-02-27 | $900.00K derived: sum of 3 quarters · filed 2024-02-27 | $1.20M 10-K · filed 2024-02-27 |
| 2021-09-30 | $300.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $600.00K derived: sum of 2 quarters · filed 2022-11-09 | $900.00K 10-Q · filed 2022-11-09 | |
| 2021-06-30 | $300.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $600.00K 10-Q · filed 2022-08-04 | ||
| 2021-03-31 | $300.00K 10-Q · filed 2022-05-05 | |||
| 2020-12-31 | $900.00K 10-K · filed 2023-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |